Acutus medical announces acceptance of the acqforce flutter abstract for presentation during the late-breaking clinical trials and first report investigations sessions at the 2023 af symposium

Carlsbad, calif., dec. 29, 2022 (globe newswire) -- acutus medical, inc. (“acutus”) (nasdaq: afib), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the acceptance of the acqforce flutter abstract titled “acqforce flutter trial clinical results: force sensing rf ablation with low flow gold tip catheter for typical flutter” for presentation during the late-breaking clinical trials and first report investigations session at the af symposium in boston. this abstract – including full study results - will be presented on friday, february 3, 2023.
AFIB Ratings Summary
AFIB Quant Ranking